Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when CLNN files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsClene extends debt maturity to Aug 2027, defers $150K monthly payments starting Sept 2026
Filed May 22, 2026 · Period ending May 18, 2026 · ~1 min read
Key Changes
-
high
Clene amended its senior secured convertible notes to push maturity from 2026 to August 2027 (or earlier if change of control occurs), buying an extra year before debt comes due.
Item 1.01 verify on EDGAR → -
high
Monthly principal and interest payments of $150,000 that were set to begin September 2026 have been deferred entirely, with all amounts now due at the August 2027 maturity date—providing near-term cash relief but concentrating repayment risk.
Item 1.01 verify on EDGAR → -
medium
Stockholders approved expanding the 2020 Stock Plan by 1,000,000 shares for employee equity compensation, which will dilute existing shareholders proportionally.
Item 5.07 verify on EDGAR → -
low
At the May 21 annual meeting, three Class III directors were elected to three-year terms through 2029, and Deloitte & Touche was ratified as auditor for fiscal 2026.
Item 5.07 verify on EDGAR →
Summary
Clene restructured its senior secured convertible debt to extend the maturity date by roughly one year to August 2027 and defer $150,000 in monthly payments that were scheduled to start in September 2026. This amendment provides immediate cash flow relief for a company that has been burning capital, but it also means the full principal and accrued interest will come due in a single balloon payment in mid-2027.
Retail investors should watch whether Clene can secure additional financing, achieve revenue milestones, or arrange a strategic transaction before that maturity date—otherwise the company may face refinancing pressure or dilutive capital raises. Separately, shareholders approved a 1,000,000-share increase to the equity compensation plan, expanding the pool available for employee and executive grants.
While routine for a growth-stage biotech, this will dilute existing holders incrementally. The annual meeting also saw three directors re-elected and the auditor ratified with strong support. Watch for Clene's next quarterly filing to see cash burn rate and runway in light of the deferred debt payments.
Section-by-Section Diff
Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On May 21, 2026, the stockholders of the Company voted at the Company’s 2026 Annual Meeting of Stockholders (the “Annual Meeting”) to approve the Clene Inc. Amended 2020 Stock Plan (the “Plan”) to increase the number of shares of common stock, par value $0.0001 per share (“Common Stock”) reserved for issuance thereunder by 1,000,000 shares.
Clene's stockholders approved an amendment to the company's 2020 Stock Plan at the annual meeting held May 21, 2026. The amendment increases the pool of common stock reserved for equity compensation by 1,000,000 shares. This expansion provides additional capacity for employee and executive equity grants. Note: these figures were previously disclosed in the company's May 5, 2026 8-K.
Event · Item 5.07 — Submission of Matters to a Vote of Security Holders
Annual meeting held May 21, 2026: directors elected, auditor ratified, executive compensation approved, stock plan expanded by 1M shares.
Added in current filing · verify on EDGAR →
An amendment to the Clene Inc. Amended 2020 Stock Plan was approved, thus increasing the number of shares of Common Stock reserved for issuance thereunder by 1,000,000 shares, based upon the following votes: For | Against | Abstained | Broker Non-Votes | 4,204,336 | 475,626 | 15,747 | 3,057,461
Shareholders approved expanding the 2020 Stock Plan by 1,000,000 shares with 4.2 million votes for versus 475,626 against. This increases the pool of shares available for employee equity compensation, which will dilute existing shareholders by approximately $150,000 the amount of the increase relative to total shares outstanding.
Show 2 minor / wording changes
Added in current filing · verify on EDGAR →
The following nominees were elected to serve as Class III directors until the expiration of their three-year term at the annual meeting of stockholders in 2029, or until their successors are duly elected and qualified, based upon the following votes: For | Withheld | Broker Non-Votes | Robert Etherington | 3,904,259 | 791,450 | 3,057,461 | Shalom Jacobovitz | 3,711,448 | 984,261 | 3,057,461 Alison H. Mosca 3,675,073 | 1,020,636 | 3,057,461
Three Class III directors were elected to serve three-year terms expiring in 2029. Robert Etherington received the most support with 3.9 million votes for, while Alison Mosca had the highest withhold votes at 1.0 million. All three nominees were elected.
Added in current filing · verify on EDGAR →
The appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for fiscal year 2026 was ratified based upon the following votes: For | Against | Abstained | 7,737,513 | 11,372 | 4,285
Shareholders ratified Deloitte & Touche LLP as the independent auditor for fiscal 2026 with overwhelming support of 7.7 million votes for versus only 11,372 against. This is a routine annual vote confirming the audit firm.
Event · Item 9.01 — Financial Statements and Exhibits
Clene filed exhibits for an amended convertible note and updated stock plan, with no narrative disclosure of terms or business impact.
Added in current filing · verify on EDGAR →
Form of Amended & Restated Senior Secured Convertible Promissory Note.
The company filed an amended and restated form of senior secured convertible promissory note. The 8-K provides no narrative detail on the amendment's terms, conversion price, maturity, interest rate, or business rationale. Investors must review the full exhibit to understand changes from the prior note form.
Added in current filing · verify on EDGAR →
Clene Inc. Amended 2020 Stock Plan.
The company filed an amended version of its 2020 Stock Plan. The 8-K provides no narrative detail on what changed — such as share reserve increases, eligibility expansions, or vesting modifications. Investors must review the full exhibit to understand the amendment's impact on dilution and compensation.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · May 28, 2026 · How we verify